ArticleMolecular nutrition & food research2026
Docosahexaenoic Acid Consumption Early in Life Improves Immune Dysfunction in High-Fat Diet-Fed Wistar Rats in a Sex-Specific Manner.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Metabolic Calibration of Female Immune Plasticity: From X-Linked Vulnerability to Precision Metabotyping.Biology · 2026Review
- Docosahexaenoic Acid Consumption Early in Life Improves Immune Dysfunction in High-Fat Diet-Fed Wistar Rats in a Sex-Specific Manner.Molecular nutrition & food research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate whether early-life docosahexaenoic acid (DHA) consumption mitigated the effects of a high-fat diet (HFD) on body composition, endocrine hormones, immune function, inflammatory biomarkers, and identify sex differences. Wistar rats were fed (PND 0-70) diets differing only in fat composition: control low-fat (10% fat, 0% arachidonic acid [ARA], 0% DHA), control high-fat (HF, 20% fat, 0% ARA, 0% DHA), or DHA HF (20% fat, 1% ARA, 2% DHA) (n = 16/group, males/females = 8/8). Plasma hormones (ELISA), inflammatory biomarkers (electrochemiluminescence), splenocytes phenotype (immunofluorescence), and ex vivo cytokine production (ELISA) after mitogen stimulation were measured. HFD did not alter body weight/composition or inflammatory profile but increased plasma glucagon-like peptide 1 (GLP-1, males, p = 0.02). In the spleen, HFD lowered transforming growth factor-beta (TGF-β) and increased interleukin (IL)-10 (females) and IL-2 production (p < 0.03). It also lowered % of regulatory T cells (Treg), B cells (males), conventional type 1dendritic cells (cDC1), and MHC-II and CD86 expression (males) (p < 0.03). DHA mitigated HFD-related changes in plasma GLP-1 (males) andTGF-β, IL-10 (females), and IL-2 production (p ≤ 0.03) and increased % of B cells (males), cDC1, MHC-II, and CD86 expression (males) (p < 0.03). DHA mitigated HFD-induced impaired Treg response and compromised adaptive immunity and antigen-presenting function in a sex-specific manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.